Madrigal press releases are available below. Search them by keyword or browse by date. Year All 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 September 2, 2026 Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference August 20, 2026 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) August 12, 2026 Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors August 6, 2026 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) August 6, 2026 Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference July 30, 2026 Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates July 21, 2026 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) July 16, 2026 Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026 July 13, 2026 Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio July 6, 2026 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
September 2, 2026 Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference
August 20, 2026 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
August 6, 2026 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
August 6, 2026 Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
July 30, 2026 Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates
July 21, 2026 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
July 16, 2026 Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026
July 13, 2026 Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio
July 6, 2026 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
